Intepirdine: Difference between revisions
CSV import |
CSV import |
||
| Line 1: | Line 1: | ||
== Intepirdine == | |||
[[File:Intepirdine.svg|thumb|right|Chemical structure of Intepirdine]] | |||
Intepirdine was | '''Intepirdine''' is a pharmaceutical compound that was investigated for its potential use in the treatment of [[Alzheimer's disease]] and other forms of [[dementia]]. It is a selective antagonist of the [[5-HT6 receptor]], a subtype of the [[serotonin receptor]] that is primarily expressed in the [[central nervous system]]. | ||
== Mechanism of Action == | === Mechanism of Action === | ||
Intepirdine | Intepirdine functions by blocking the 5-HT6 receptor, which is believed to play a role in the regulation of [[neurotransmitter]] release, including [[acetylcholine]], [[dopamine]], and [[glutamate]]. By inhibiting this receptor, intepirdine was hypothesized to enhance cognitive function and improve memory in patients with Alzheimer's disease. | ||
== Clinical | === Clinical Development === | ||
Intepirdine | Intepirdine was initially developed by [[GlaxoSmithKline]] and later acquired by [[Axovant Sciences]]. It underwent several [[clinical trials]] to assess its efficacy and safety in patients with Alzheimer's disease. Despite initial promise, the results of the pivotal phase III trial, known as the MINDSET study, did not demonstrate significant improvement in cognitive function compared to [[placebo]]. | ||
== | === Discontinuation === | ||
Following the disappointing results from the MINDSET study, Axovant Sciences announced the discontinuation of further development of intepirdine for Alzheimer's disease. The decision was based on the lack of efficacy observed in the clinical trials, which did not support the continuation of its development for this indication. | |||
== | === Potential Applications === | ||
Although intepirdine was not successful in treating Alzheimer's disease, research into 5-HT6 receptor antagonists continues, as they may hold potential for other [[neurological disorders]]. The exploration of alternative therapeutic targets and combinations with other treatments remains an area of active investigation. | |||
== Related Pages == | |||
* [[Alzheimer's disease]] | * [[Alzheimer's disease]] | ||
* [[ | * [[Serotonin receptor]] | ||
* [[Neurotransmitter]] | |||
* [[Clinical trial]] | * [[Clinical trial]] | ||
[[Category:Pharmaceutical drugs]] | [[Category:Pharmaceutical drugs]] | ||
[[Category: | [[Category:Neurology]] | ||
[[Category: | [[Category:Serotonin receptor antagonists]] | ||
Latest revision as of 04:02, 13 February 2025
Intepirdine[edit]
Intepirdine is a pharmaceutical compound that was investigated for its potential use in the treatment of Alzheimer's disease and other forms of dementia. It is a selective antagonist of the 5-HT6 receptor, a subtype of the serotonin receptor that is primarily expressed in the central nervous system.
Mechanism of Action[edit]
Intepirdine functions by blocking the 5-HT6 receptor, which is believed to play a role in the regulation of neurotransmitter release, including acetylcholine, dopamine, and glutamate. By inhibiting this receptor, intepirdine was hypothesized to enhance cognitive function and improve memory in patients with Alzheimer's disease.
Clinical Development[edit]
Intepirdine was initially developed by GlaxoSmithKline and later acquired by Axovant Sciences. It underwent several clinical trials to assess its efficacy and safety in patients with Alzheimer's disease. Despite initial promise, the results of the pivotal phase III trial, known as the MINDSET study, did not demonstrate significant improvement in cognitive function compared to placebo.
Discontinuation[edit]
Following the disappointing results from the MINDSET study, Axovant Sciences announced the discontinuation of further development of intepirdine for Alzheimer's disease. The decision was based on the lack of efficacy observed in the clinical trials, which did not support the continuation of its development for this indication.
Potential Applications[edit]
Although intepirdine was not successful in treating Alzheimer's disease, research into 5-HT6 receptor antagonists continues, as they may hold potential for other neurological disorders. The exploration of alternative therapeutic targets and combinations with other treatments remains an area of active investigation.
